Erlotinib in Treating Patients With Recurrent or Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow
the growth of the tumor. Phase II trial to study the effectiveness of erlotinib in treating
patients who have recurrent or metastatic colorectal cancer.